Csl behring sec filings
WebCSL communicates accurate, relevant and timely information on our GHG emissions and progress to date to stakeholders through our Annual Report, Carbon Disclosure Project (CDP) submission, the Australian Governments National Greenhouse and Energy Reporting and other appropriate avenues. CHARTER OF CORPORATE GOVERNANCE AND … WebCSL Behring is a global leader in developing and delivering high-quality medicines that treat people with rare and serious diseases. Our treatments offer promise for people in more than 100 countries living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. Our Products
Csl behring sec filings
Did you know?
WebMarburg, Germany. CSL Behring, a subsidiary of CSL Limited, developed a pandemic vaccine (H1N1) and signed a 180 million dollar contract with the US Department of Health and Human Services (HHS) to provide bulk H1N1 influenza antigen. They use ICONICS software in their FDA-approved filing and packaging facility in Marburg, Germany, to … WebMar 22, 2013 · Agency Court Filings. Appellate Court Briefs and Petitions filed by the General Counsel; ... [Sec 8(d)/Unilateral Changes] Participants. Participant ... (312)460 …
WebJun 25, 2024 · CSL Behring has struck a deal to buy uniQure’s late-phase hemophilia B gene therapy AMT-061 for $450 million upfront. The agreement will catapult CSL to the front of the race to bring a ... WebJan 18, 2024 · Melbourne, Australia and St. Gallen, Switzerland, 18 January 2024 – CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY), today published the offer prospectus regarding its public tender offer for all publicly held registered shares of Vifor Pharma Ltd. …
WebMar 8, 2024 · CSL Behring says it is on track to file for approval of its hemophilia B gene therapy by the end of June after releasing pivotal data showing statistical superiority over current standard-of-care ...
WebJan 4, 2024 · Manufacturer: CSL Behring LLC Indication: HEMGENIX is an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with Hemophilia B (congenital Factor IX deficiency) who:
WebCompany profile page for CSL Behring LLC including stock price, company news, press releases, executives, board members, and contact information can i hear the musicWebMar 8, 2024 · CSL Behring says it is on track to file for approval of its hemophilia B gene therapy by the end of June after releasing pivotal data showing statistical superiority over … fitzgerald houseWebCSL.com CSL Calendar 2024 Key Dates 19 August Annual profi t and fi nal (ABN 99 051 588 348) will be held online on dividend announcement 10 September Shares traded ex-dividend 11 September Record date for fi nal dividend 9 October Final dividend paid 14 October Annual General Meeting 31 December Half Year ends 2024 Key Dates fitzgerald honda germantownWebMay 6, 2024 · A global leader in treating bleeding disorders, CSL Behring has been delivering innovations for the hemophilia patient community for more than 30 years. The company reported more than $1... fitzgerald hotel washington georgiaWebCSL Behring has locations to serve patients around the globe. Please find all contact information below. Headquarters CSL Behring Corporate Headquarters phone: +1 610-878-4000 fax: +1 610-878-4009 1020 First Avenue PO Box 61501 King of Prussia, PA 19406-0901 USA Regional Sales Offices R&D and Manufacturing Locations fitzgerald hotel and casinoWebDec 14, 2024 · CSL has offered to acquire Vifor Pharma in an all-cash public tender offer to acquire all publicly held Vifor Pharma shares for US$179.25 per Vifor Pharma share, … fitzgerald hotel and casino las vegasWebFinancial Calendar CSL Limited. Investors > Financial Calendar. Filter by Year: 2024 2024 2024 2024. 14 Feb 2024 Time: 11:00 to 12:00. fitzgerald hurleys araglen